Surrozen, Inc./DE SEC filings SRZN
Surrozen, Inc./DE has 496 filings in SEC EDGAR's recent list, going back to Sep 18, 2020. Its latest annual report, Form ARS, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (results of operations, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Aug 7, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | May 23, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| EFFECT | Filing | May 1, 2025 | — |
| CORRESP | Letter to the SEC | Apr 29, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2025 | — |
| D | Filing | Apr 8, 2025 | — |
| EFFECT | Filing | Apr 25, 2024 | — |
| CORRESP | Letter to the SEC | Apr 23, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2024 | — |
| D | Filing | Apr 19, 2024 | — |
| NT 10-K | Filing | Apr 2, 2024 | Apr 2, 2024 |
| EFFECT | Filing | Apr 6, 2023 | — |
| EFFECT | Filing | Apr 5, 2023 | — |
| EFFECT | Filing | Dec 19, 2022 | — |
| CORRESP | Letter to the SEC | Dec 15, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2022 | — |
| EFFECT | Filing | Apr 5, 2022 | — |
| CORRESP | Letter to the SEC | Apr 1, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2022 | — |
| EFFECT | Filing | Mar 29, 2022 | — |
| EFFECT | Filing | Nov 9, 2021 | — |
| CORRESP | Letter to the SEC | Nov 8, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2021 | — |
| CERT | Filing | Aug 11, 2021 | — |
| 8-A12B | Filing | Aug 11, 2021 | — |
| 25 | Filing | Aug 11, 2021 | — |
| 425 | Form 8-k | Aug 2, 2021 | — |
| 425 | Form 8-k | Jul 30, 2021 | — |
| EFFECT | Filing | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| 425 | Filing | Jul 9, 2021 | — |
| 425 | Filing | Jun 25, 2021 | — |
| CORRESP | Letter to the SEC | Jun 24, 2021 | — |
| 425 | Filing | Jun 17, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2021 | — |
| 425 | Filing | Jun 2, 2021 | — |
| 425 | Filing | May 24, 2021 | — |
| NT 10-Q | Filing | May 18, 2021 | Mar 31, 2021 |
| 425 | 8-k | May 14, 2021 | — |
| 425 | Filing | May 7, 2021 | — |
| 425 | 8-k | Apr 15, 2021 | — |
| EFFECT | Filing | Nov 18, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CERT | Nyse american certification | Nov 10, 2020 | — |
| 8-A12B/A | Filing | Nov 4, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| CERT | Nyse certification | Oct 26, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| 8-A12B | Form 8-a12b | Oct 19, 2020 | — |
| DRS | Filing | Sep 18, 2020 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SRZN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1824893
- Former names
- Consonance-HFW Acquisition Corp. (until Aug 11, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.